ABSTRACT
The results at 5 years of an adjuvant chemotherapy trial in primary Ewing's sarcoma, started in 1973, are presented. Twenty-three eligible patients were treated with radiotherapy (60 Gy) to the tumor site and given polychemotherapy either using the E3 protocol (12 patients) or the E76 protocol (11 patients). Overall survival at 5 years was 37%, with 34% disease-free survival. There was no significant difference between the two chemotherapy groups. Only three local relapses and one major orthopedic failure were reported. Among the distal relapses, no metastases to the brain have been observed. These results are encouraging and show a clear improvement over the classical survival rate. However, further improvement is necessary and may be obtained by using new active drugs, as well as earlier and probably more aggressive cyclic chemotherapy. But primary surgical amputation and prophylactic CNS irradiation are not indicated for treatment of primary Ewing's sarcoma.
Subject(s)
Sarcoma, Ewing/drug therapy , Clinical Trials as Topic , Cyclophosphamide/therapeutic use , Dactinomycin/therapeutic use , Doxorubicin/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Follow-Up Studies , Humans , Procarbazine/therapeutic use , Sarcoma, Ewing/radiotherapy , Vincristine/therapeutic useABSTRACT
An unicellular alga, Chlorella pyrenoidosa, which had been reported to protect C3H mice against sarcoma BP8, is shown, when injected in Freund's incomplete adjuvant, to modulate the antibody synthesis induced by immunization with a hapten-carrier complex. C. pyrenoidosa appeared to be able to initiate an antigenic competition between hapten and carrier determinants of the antigen molecule during antibody synthesis, and thus it could be speculated that C. pyrenoidosa modulates the immune response at the macrophage level.
Subject(s)
Antibody Formation , Chlorella/physiology , Anaphylaxis/immunology , Animals , Guinea Pigs , Hypersensitivity, Delayed/immunology , Skin TestsSubject(s)
Antineoplastic Agents/administration & dosage , Bone Neoplasms/drug therapy , Sarcoma, Ewing/drug therapy , Bone Neoplasms/radiotherapy , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Doxorubicin/administration & dosage , Drug Administration Schedule , Drug Therapy, Combination , Humans , Methotrexate/administration & dosage , Procarbazine/administration & dosage , Sarcoma, Ewing/radiotherapy , Vincristine/administration & dosageABSTRACT
The different steps of a microassay for the quantitation of cytotoxic antitumor antibody, are studied in detail. It is shown that the use of 125I-Iododeoxyuridine as the target cell label, at the end of the assay, after action of serum and complement, allows the advantages available with this isotopic label to be retained and to avoid the main disadvantage due to its non specific toxicity for the target cells. Furthermore, this technique is shown to be able to detect non only a killer effect of immune sera on specific target cells with complement but also an additionnal static effect of DNA synthesis : this effect is complement dependent and transitory.
Subject(s)
Antibodies, Neoplasm/analysis , DNA, Neoplasm/biosynthesis , Idoxuridine , Animals , Cell Survival/drug effects , Culture Techniques , Cytotoxicity Tests, Immunologic , Female , Idoxuridine/pharmacology , Methylcholanthrene , Mice , Mice, Inbred C3H , Neoplasms, Experimental/chemically induced , Neoplasms, Experimental/immunology , Sarcoma/chemically induced , Sarcoma/immunologyABSTRACT
Blastic stimulation of lymphocytes by antigens or mitogens is usually measured by 3H-TdR labelling of DNA synthesis in 4 to 7 days. However, it has been recently shown, first in mice and guinea pigs, then in men, that it is possible to detect an earlier event by measurement of protein synthesis with 3H-Leucine in a few hours. The work presented here is devoted to determine the optimal conditions of such a short term assay in man. The technique we propose is described. Preliminary clinical results in lymphomas patients, compared to "in vitro" skin tests, are encouraging.
Subject(s)
Leucine/metabolism , Lymphocyte Activation , Breast Neoplasms/immunology , Cells, Cultured , Dose-Response Relationship, Drug , Humans , Isotope Labeling , Lectins/pharmacology , Lymphoma/immunology , Methods , Protein Biosynthesis , Time FactorsABSTRACT
A case of a positive 131-I-19-iodocholesterol scan caused by a cortisol secreting adrenal carcinoma and its hepatic metastases is reported.
